title: Identification and functional signature of genes regulated by structurally different ABL kinase inhibitors.
abstract: Dasatinib is an ATP-competitive, multi-targeted SRC and ABL kinase inhibitor that can bind BCR-ABL in both the active and inactive conformations. From a clinical standpoint, dasatinib is particularly attractive because it has been shown to induce hematologic and cytogenetic responses in imatinib-resistant chronic myeloid leukemia patients. The fact because the combination of imatinib and dasatinib shows the additive/synergistic growth inhibition on wild-type p210 BCR-ABL-expressing cells, we reasoned that these ABL kinase inhibitors might induce the different molecular pathways. To address this question, we used DNA microarrays to identify genes whose transcription was altered by imatinib and dasatinib. K562 cells were cultured with imatinib or dasatinib for 16 h, and gene expression data were obtained from three independent microarray hybridizations. Almost all of the imatinib- and dasatinib-responsive genes appeared to be similarly increased or decreased in K562 cells; however, small subsets of genes were identified as selectively altered expression by either imatinib or dasatinib. The distinct genes that are selectively modulated by dasatinib are cyclin-dependent kinase 2 (CDK2) and CDK8, which had a maximal reduction of <5-fold in microarray screen. To assess the functional importance of dasatinib regulated genes, we used RNA interference to determine whether reduction of CDK2 and CDK8 affected the growth inhibition. K562 and TF-1BCR-ABL cells, pretreated with CDK2 or CDK8 small interfering RNA, showed additive growth inhibition with imatinib, but not with dasatinib. These findings demonstrate that the additive/synergistic growth inhibition by imatinib and dasatinib may be mediated in part by CDK2 and CDK8.
authors.affiliation: First Department of Internal Medicine, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Nunoda
authors.forename: T
authors.initials: T
authors.lastname: Tauchi
authors.forename: T
authors.initials: T
authors.lastname: Takaku
authors.forename: S
authors.initials: S
authors.lastname: Okabe
authors.forename: D
authors.initials: D
authors.lastname: Akahane
authors.forename: G
authors.initials: G
authors.lastname: Sashida
authors.forename: J H
authors.initials: JH
authors.lastname: Ohyashiki
authors.forename: K
authors.initials: K
authors.lastname: Ohyashiki
mesh_terms: D001549:Benzamides; D049109:Cell Proliferation; D004249:DNA Damage; D004260:DNA Repair / Q000235:genetics; D000069439:Dasatinib; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005786:Gene Expression Regulation / Q000187:drug effects*; D006801:Humans; D000068877:Imatinib Mesylate; D020014:K562 Cells; D020411:Oligonucleotide Array Sequence Analysis; D016374:Oncogene Proteins v-abl / Q000037:antagonists & inhibitors*; D009857:Oncogenes; D010879:Piperazines / Q000494:pharmacology*; D011743:Pyrimidines / Q000494:pharmacology*; D034741:RNA, Small Interfering; D013844:Thiazoles / Q000494:pharmacology*
chemical_list: D001549:Benzamides; D004791:Enzyme Inhibitors; D016374:Oncogene Proteins v-abl; D010879:Piperazines; D011743:Pyrimidines; D034741:RNA, Small Interfering; D013844:Thiazoles; D000068877:Imatinib Mesylate; D000069439:Dasatinib